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Abstract: “Cancer 2015” is a longitudinal and prospective cohort. It is a phased study whose 
aim was to pilot recruiting 1000 patients during phase 1 to establish the feasibility of 
providing a population-based genomics cohort. Newly diagnosed adult patients with solid 
cancers, with residual tumour material for molecular genomics testing, were recruited into 
the cohort for the collection of a dataset containing clinical, molecular pathology, health 
resource use and outcomes data. 1685 patients have been recruited over almost 3 years from 
five hospitals. Thirty-two percent are aged between 61–70 years old, with a median age of  
63 years. Diagnostic tumour samples were obtained for 90% of these patients for multiple 
parallel sequencing. Patients identified with somatic mutations of potentially “actionable” 
variants represented almost 10% of those tumours sequenced, while 42% of the cohort had 
no mutations identified. These genomic data were annotated with information such as cancer 
site, stage, morphology, treatment and patient outcomes and health resource use and cost. 
This cohort has delivered its main objective of establishing an upscalable genomics cohort 
within a clinical setting and in phase 2 aims to develop a protocol for how genomics testing 
can be used in real-time clinical decision-making, providing evidence on the value of precision 
medicine to clinical practice. 




Despite recent data showing trends of improving cancer survival rates worldwide, cancer is now the 
leading cause of disease burden and mortality. Indeed, incidence rates are increasing such that the 
number of new cases is projected to increase from 14.1 million in 2012 to almost 25 million over the 
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next two decades [1]. This projected rise of ~75% in cancer cases coincides with the advent of “personalized, 
precision or stratified” medicine, with an increasing number of molecularly targeted therapies in 
development and receiving approval to treat tumours in patients with defined, “actionable” genetic 
mutations. This shift towards targeted therapies is not only challenging the delivery of oncology and 
pathology services but also wider aspects of the health care system, including the funding model, 
particularly as these therapies are expensive, which combined with a growing incidence of cancer is likely 
to contribute to escalating health costs that are unsustainable. 
Despite a sense of inevitability, there remain a number of research and clinical questions that need to 
be addressed to appropriately prepare for the era of genomic medicine. With this in mind, “Cancer 2015” 
was devised to establish a prospective and longitudinal, population-based cancer genomic cohort with 
the main purpose of determining how molecular pathology could be incorporated into the routine care 
of cancer patients so that they could benefit from molecularly targeted therapies in place of often toxic 
and ineffective chemotherapy agents. The main objectives of Cancer 2015 are summarized as follows: 
 Establishment of a database consisting of biospecimens as well as clinical and epidemiological 
data to be used as a clinical and research resource. 
 To screen cancer tumour DNA isolated from diagnostic tissue samples from patients independent 
of cancer subtype, to determine if any mutations are present that may potentially be of clinical and 
therapeutic significance. 
 To yield data on the total population frequency of these mutations and identify patients that may 
benefit from therapeutics targeted against these “actionable” mutations. 
 To collect health-related quality of life (HRQoL) responses longitudinally, and link in administrative 
health care resource use and cost data, in order to facilitate the assessment of the value of targeted 
therapies, and cancer care more generally. 
Phase 1 (pilot) of the study commenced in November 2011 with the overall objective to recruit  
a minimum of 1000 new incident cancers from five hospitals in the state of Victoria [2] (which comprises 
~25% of the Australian population). All solid cancers independent of histotype, were included in order 
to reflect the cancer burden sampling from a cross-section of the community representing both metropolitan 
and regional patients. The pilot was successful in recruiting over 1600 patients to the end of September 
2014, from both metropolitan and regional hospitals. Data presented herein demonstrate our progress to 
date, describing preliminary, proof-of-principle results of one of only a few population-based genomic 
cohorts that are being undertaken worldwide [3–5]. 
2. Results 
2.1. Cohort Characteristics 
The cohort recruited patients using a study protocol as summarized in Figure 1. Between November 
2011 and September 2014 (phase 1), 1685 patients with newly diagnosed cancers were consented into 
the Cancer 2015 Cohort, surpassing its milestone target of 1000. The patient demographics and some of 
their clinical characteristics are shown in Table 1. Approximately 34% of participants were between  
61–70 years of age at diagnosis with a median age of 63.2 (range 19–92) years, compared with the 
average age of cancer diagnosis in Australia reported as 65.4 years in 2009 [6]. Recruitment was generally 
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balanced by gender, with the exception of the Peter MacCallum Cancer Centre, which is a specialist cancer 
treatment centre for many male-dominated cancer types as well as a tertiary radiotherapy centre. The 
median period of time in which patients were enrolled into the Cancer 2015 cohort after diagnosis was 
26 days. Of the 1685 participants in the cohort at the end of phase 1, 233 were deceased (13.8%), whilst 
a further 63 (3.7%) had requested to withdraw from the study either in written or verbal form (Table 1). 
 
Figure 1. Schematic of pathway/protocol of patient recruitment to the cancer 2015 cohort. 
Table 1. Demographic characteristics of cancer 2015 cohort participants. 
Characteristic N % 
Total Consented: 1685  
Deceased 233 13.8 
Withdrawn 63 3.7 
Male 916 54.0 
Female 769 45.5 
Recruited from Institution:   
Cabrini Hospital 322 19.0 
Geelong Hospital 284 16.7 
Peter MacCallum Cancer Centre 523 30.9 
Royal Melbourne Hospital 362 21.5 
Warrnambool Hospital 194 11.5 
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Table 1. Cont. 
Characteristic N % 
Regional Statistics:   
Metropolitan 936 57.7 (69) 
Non-Metropolitan 685 42.3 (31) 
Age (years and 10-yr deciles)   
Median 63.2  
11–20 1 0.1 
21–30 27 1.6 
31–40 73 4.4 
41–50 204 12.2 
51–60 374 22.3 
61–70 573 34.2 
71–80 317 18.9 
81–90 103 6.1 
91–100 3 0.2 
Region of Origin (Birth):   
Africa 22 1.3 (2.5) 
Asia 70 4.2 (4.8) 
Australia (inc. Oceania) 1222 72.5 (67.6) 
Europe 268 15.9 (24.3) 
North America 9 0.5 (0.4) 
South America 2 0.1 (0.4) 
Marital Status*:   
Never married 69 4.1 
Married  803 47.7 
Divorced 97 5.8 
Widowed 108 6.4 
Separated 19 1.1 
Not stated 575 34.1 
Education Level*:   
Primary 51 3.0 
Junior Secondary 168 10.0 
Senior Secondary 148 8.8 
Graduate 105 6.2 
Post-graduate 44 2.6 
No formal education 9 0.5 
Not stated 1146 68.0 
Disease Presentation Mode:   
Symptomatic 1081 64.2 
Asymptomatic/incidental 196 11.6 
Screening 361 21.4 
Not Stated 38 2.3 
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Table 1. Cont. 
Characteristic N % 
Performance Status (ECOG):   
0 1066 63.3 
1 400 23.7 
2 121 7.2 
3 42 2.5 
4 4 0.2 
Charlson Co-Morbidities Index:   
0–5 1448 85.9 
6–10 58 3.4 
>10 170 10.1 
Private Hospital Insurance:   
Yes 694 41.2 
No 948 56.3 
Smoking Status:   
Daily 209 12.4 
Weekly 13 0.8 
Irregular 25 1.5 
Ex-smoker 747 44.3 
Never Smoked 630 37.4 
Past History of Cancer:   
Yes 303 18.0 
No 1336 79.3 
Family History of Cancer (1st/2nd  
order blood relative): 
  
Yes 1106 65.6 
No 507 30.1 
Hereditary Syndromes 10 0.6 
Blood Samples Obtained:   
Received 1505 89.3 
Unavailable/Insufficient tissue 172 10.2 
Quality of Life Questionnaire  
responses: 
  
Baseline 1606 95.3 
Follow-up 1271 75.4 
Medicare/Pharmaceutical Benefit  
Scheme Co-Consent 
1590 94.4 
*: Data capture of marital status and level of education was not initiated until 12 months after cohort start; 
Percentages in parentheses where given represent proportions of the population of Victoria [2]. 
Figure 2A presents the various solid cancer histotypes and associated clinical cancer stage of the 
patients in Phase 1. Whilst the cohort successfully accrued the expected major cancer histotypes such as 
breast, lung, colorectal and prostate cancer, it has also managed to recruit a substantial number of patients 
with less common cancers such as head and neck, bone/soft tissue (BST), renal, bladder and, to a lesser 
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extent, cancer of unknown primary. A comparison of Cancer 2015 histotype numbers with the incidence 
in Victoria is presented inset as Figure 2B. These comparisons are depicted as the difference between 
the Cancer 2015 Cohort accrual rate and the Victorian Cancer Registry (VCR) 2011 census of cancer 
incidence [2]. Thus, zero percent differential depicts identical rates between the cohort and registry. 
 
Figure 2. (A) Patient diagnoses in the Cancer 2015 Cohort separated into different tumour 
histo-types and clinical stage (as colour labelled in legend). Note: A minority of patients  
(n = 50) have tumours that fall into less common cancers such as skin, vulvovaginal, penile 
and urothelial cancers; (B) The variation between the Cancer 2015 Cohort accrual rate, 
expressed as a percentage of total cancers and separated by cancer histotype, compared with 
the VCR 2011 census of cancer incidence in Victoria (solid-cancers only; removal of 
paediatric and haematological cancers; Note: Melanoma incidences represent advanced stages 
only). Positive percentage differential reflect recruitment of patients with stated cancer 
histotype greater than published Victorian incidences. 
Whilst the cohort was mostly proportionate to the VCR census data of 2011, the rates of accrual of 
some types of cancer may have been biased by the cohort’s initial selection of hospitals. Notably there 
is a slight (<−1%) under-representation, in general, of gynaecological cancers due to the lack of  
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a gynaecological cancer centre in Phase 1. Conversely, the cohort has a higher than expected rate of accrual 
of patients with head and neck cancers (>+8%) most probably due to the Peter MacCallum Cancer Centre 
being one of the major radiotherapy centres for Victoria. Expansion to a broader range of hospital 
oncology services should correct for any other ascertainment biases in future phases. The cohort currently 
offers a fairly even representation of each cancer-stage (I–IV; data not shown). 
2.2. Data Completion 
The clinical data elements collected by the Cancer 2015 Cohort were centred on a modified Core 
Clinical Cancer Data Set [7] as published by the Australian Institute of Health and Welfare (AIHW) and 
National Cancer Control Initiative 2004. At least 80% of these individual data elements have been fully 
completed after audit of the data (excluding optional fields) in the registry (Supplementary Table S1). 
Ongoing data auditing and cleansing will significantly improve these completion rates as the pilot 
matures as well as determine the accuracy of data collection via random sampling audit. 
Cancer stage, as described above, was collected in >85% of the patient cohort, additional indicators 
such as the ECOG [8] performance status (95% complete) and Charlson Index [9] of co-morbidities 
(90% complete) yield data on the patient’s general capabilities and predictive mortality. Note that the 
majority of the cohort (62%) belong to ECOG category 0 (data not shown); described as “Fully active, 
able to carry on all pre-disease performance without restriction”, while 80% of patients have a Charlson 
Index score of 1 or less, indicative of a low level of co-morbid disease. These data will be important for 
identifying patients who may be suitable for clinical trials (see discussion). 
2.3. Genomic Assay of Biospecimens 
The majority of patients (94%) who have consented to Cancer 2015 had an initial blood sample drawn 
and processed into plasma and blood/buffy coat pellets as part of the recruitment protocol. Patient poor 
health was the main reason that samples were not obtained. Furthermore, approximately 10% of these 
patients with a base blood sample prior to treatment also have a repeat blood sample obtained at either 
the 3–6 or 12 month follow-up time points. With respect to tumour pathology samples, 1505 patient 
samples have been received from the 1685 patients recruited (90%) in phase 1. In a cross-section of 
1157 samples received mid-phase 1 depicted in Figure 3A, 954 successfully yielded DNA of sufficient 
quantity and quality for the TruSeq™ Cancer gene variant testing (Illumina, San Diego, CA, USA), of 
which 556 samples (58%) had at least one somatic variant identified, noting that 398 had no somatic 
variant identified. A negative result using this assay may arise due to a disease causing somatic variant 
occurring outside the regions targeted by the assay. In addition the analytical process employed in this 
study was not suitable for detecting copy number variations or structural rearrangements. For the remaining 
samples (17.5%), testing was not possible due to quality control issues (typically DNA < 10 ng/µL) or lack 
of tissue availability. Furthermore, there were a number (90) of advanced cancer patients (Figure 3A) 
identified with gene variants deemed potentially “actionable”, defined as relatively healthy individuals 
by ECOG rating who may have been eligible for clinical trials of new targeted therapies or with 
previously approved drugs. Improvement to the pathology tissue requisition process is ongoing and 
involves either increasing the number of slides requested of tumour samples for some tumour types, limited 
macro-dissection of the tumour from “normal” tissue and/or quality assurance enhancements in the process 
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or sensitivity of the variant assay testing in updated release versions (Illumina TruSight™) using optimised 
chemistry. This is discussed in detail in the publication centred on the molecular pathology/genomics 
aspects of the cohort [10], though an overall impression of the rates of gene mutations using our TruSeq™ 
cancer gene panel is depicted in Figure 3B where it is observed that not unexpectedly, TP53 is the most 
frequently mutated gene within our solid cancer sample collection from phase 1. 
 
Figure 3. (A) The number of Cancer 2015 patients that have had tumour sample DNA 
sequenced, binned into those with at least one gene somatic variant identified; having advanced 
cancer (Stage Group ≥3); having an Eastern Co-operative Oncology Group (ECOG) 
Performance status of ≤2 (“no worse than ambulatory and capable of all self care but unable 
to carry out any work activities. Up and about more than 50% of waking hours”) and finally 
the variant(s) are deemed “actionable” (i.e., approved drugs available or drugs in clinical 
trials); (B) Comparison of the number of mutations observed per gene represented overall 
across all solid tumour histo-types in the cohort. 
2.4. Patient Follow Up 
The longitudinal nature of the cohort is an important asset of Cancer 2015. Follow-up with patients 
is progressing well such that the rate of successful follow-up is over 90% at 3–6 month post-consent and 
approximately 75% at 12 months (Figure 4A). Median first follow up interval is 5.9 months, with an 
overall median of 8.7 months (includes multiple follow-ups; data not shown). An analysis of overall 
survival rates for patients in the Cancer 2015 cohort at time points of 12, 24 and ~36 months post study 
start-up, finds 92.9%, 90.5% and 86.2% of patients alive, respectively, with a small number of patients 
having requested to be withdrawn from the study (Figure 4B), the majority preferring no further contact 
with the study (but satisfied for research to continue with their samples) for reasons such as their cancer 
is in remission and thus a desire to move on. The cohort has achieved a high compliance rate with respect 
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to follow up PROM questionnaires (~75% at first follow-up; data not shown) using return-paid postal 
correspondence. These repeat time points for the HRQoL questionnaires will be pivotal for determining 
health outcomes over time, including quality adjusted life years (QALYs) which are often used in health 
economic evaluations. These outcomes, together with the resource use and costs derived from the linkages 
with the Medicare Benefits Schedule (MBS) and the Pharmaceutical Benefits Scheme (PBS); and 
hospitalisation records, offer the necessary evidence to begin to understand the economic implications 
of targeted cancer therapies using genomic testing. 
 
Figure 4. (A) The percentage of Cancer 2015 patients with at least one follow-up, binned 
into time periods 3–6, 12 and 24 months post-registration into phase 1 of the study;  
(B) Percentage of Cancer 2015 patients that have either deceased or withdrawn consent to 
the study as of end of phase 1 (level 1 = no contact but patient approves continuation of 
collecting data, level 2 = no contact but patient requests to stop collecting data, level 3 = no 
contact and patient requests removal of data and destruction of biospecimens). 
Dependent on future funding, Cancer 2015 plans to increase its rate of biospecimen follow-up to form 
a resource pivotal for emerging areas such as circulating tumour DNA plasma biomarker studies [11].  
To date, additional follow-up blood samples have been obtained from 152 individuals. 
3. Discussion 
In Phase 1 of this study, Cancer 2015 was set the task of establishing the feasibility of its program of 
work. It has successfully implemented a prospective, cancer patient recruitment program across five 
hospitals within the state of Victoria (Australia). The feasibility of patient accrual across hospitals from 
wide geographic distances encompassing both metropolitan (Melbourne and Geelong) and regional 
cities (Warrnambool) has been successfully demonstrated. This is important to prove ease of access to 
genomic testing for patients recruited from large and diverse geographic regions. The molecular pathology 
component of the first phase of Cancer 2015 demonstrated the feasibility of adopting next generation 
sequencing for mutational profiling of tumour samples [12] from Victorian metropolitan and regional 
centres and importantly delivered on its two main outcomes of test numbers and the viability of cancer 
gene panel testing. The longitudinal follow up of clinical data, HRQoL responses, together with data 
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linkage of health care resource use has also been achieved, and it will ultimately yield evidence to evaluate 
the cost, outcomes and value of integrating genomics-guided interventions into standard care and treatment. 
Notably, Cancer 2015 has provided data to support genomics-targeted recruitment of patients into 
clinical trials. Near the midpoint of phase 1, 90 advanced stage cancer patients have been identified as 
having “actionable” somatic gene variants that potentially could be treated either via approved drugs or 
those currently in clinical trials. Furthermore, initial analyses of the cohort data have demonstrated 
significant differences in mutation type and frequency compared with those previously reported by 
institutional series [12]. 
Apart from patient accrual in the major cancer histotypes, the cohort has also achieved significant 
accrual of patients with rarer and more importantly, less well-studied (and understood) cancers such as 
head and neck (H&N), bone and soft tissue (BST) and cancer of unknown primary (CUP). As such the 
cohort is well placed to provide unique data to support a new classification for at least some cancers 
(e.g., H&N, CUP), and this may open unexpected avenues for investigation and treatment in these poor 
prognosis tumours. The cohort has also identified actionable mutations in tumours not usually thought 
to harbour such genetic changes, raising new therapeutic opportunities, e.g., Ras-Raf or Akt-PI3K pathway 
in CUP. The breadth and depth of the cohort, in terms of coverage of cancer and the identification of new 
mutations will provide a platform from which to undertake unique health economic analyses of cancer 
care and more specifically targeted therapies. 
A key goal of the current, Phase 2 of the Cancer 2015 cohort is to implement genomic testing/ 
screening on a population-level for Victorian cancer patients in real-time (turn around time < 10 working 
days) for a wide range of clinically actionable somatic mutations using next generation sequencing. 
Advances in genome technology continue apace. Thus a significant challenge facing Cancer 2015 is to 
ensure a clinically robust and valid assay can continue to be delivered while incorporating relevant 
advances in cancer genomics and analytical genomic technology. The identification of actionable 
mutations will aid clinical cancer care by identifying approved, targeted cancer therapeutics and for 
many patients it will increase access to revolutionary clinical trials currently underway worldwide [13–18]. 
4. Experimental Section 
Given the complex nature of establishing a multi-site, multi-histotype cohort, Cancer 2015 was first 
funded (by the Victorian Cancer Agency) as a pilot study. The feasibility and basic infrastructure was 
established in Phase 1 to enable patient recruitment to commence at five Victorian hospital sites; two 
capital city public hospitals, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital; a city 
private hospital, Cabrini Hospital; and non-capital metropolitan and regional public hospitals, Geelong 
(Barwon Health) and Warrnambool Hospitals (SouthWest Health), respectively. 
4.1. Study Design 
Figure 1 provides an outline of the protocol for prospective patient recruitment into this study. Once 
a patient was diagnosed with cancer after pathology assessment and subsequent referral for review to  
a clinician or surgeon, those that appropriately conformed to the Cancer 2015 eligibility criteria (see 
below) after review of medical records, were approached for their consent to this study by interview. 
Each hospital participating in the Cancer 2015 Cohort was resourced by 1–2 research nurses, with the 
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responsibility for co-ordinating and performing patient consents onsite and the centralization of the 
cohort administration and database within the study centre (Peter MacCallum Cancer Centre). Eligible 
patients included those with a new, pathologically confirmed diagnosis of solid-tumour cancer, independent 
of cancer histotype and stage; tumour accessible to biopsy and ideally prior to interventions such as 
surgery, chemo- and/or radiotherapy having commenced; and with a previous history of cancer being 
permitted. Patients were excluded if they were under 18 years of age or otherwise incapable of informed 
consent; also if the diagnosed cancer was most likely a recent (<12 months) recurrence of  
a previous incidence. This study was conducted in accordance with the Declaration of Helsinki and 
approved by the Human Research Ethics Committees of all the participating hospitals. 
4.2. Biospecimens 
Eligible patients who consented agreed to the collection of their diagnostic archival tumour block 
from pathology laboratories for the purposes of next-generation sequencing of the DNA isolated from 
the tumour tissue for targeted cancer gene panels. Moreover, patients also consented to the collection of 
18 mL of blood for the purposes of distinguishing somatic from germline variants, if identified. However, 
apart from validation assays germline variants were not routinely tested during phase 1 due to prohibitive 
assay cost. Blood samples were processed as soon as possible (b/w 2–4h at Peter MacCallum and Royal 
Melbourne Hospital but often the next day from other participating hospitals), fractionating into either 
plasma and blood cell pellets or plasma and buffy coat aliquots. The potential benefits and implications 
associated with the use of tumour and/or blood DNA for the patient and their immediate family were 
clearly articulated both in the patient information and consent form and by the research nurse involved 
in their recruitment into the cohort. Patients have the capacity to refuse to be contacted if research results 
are identified that has implications for them or their families according to the principles within the 
National Statement on Ethical Conduct in Human Research [19]. 
During the pilot phase of the study, the Molecular Pathology Department at Peter MacCallum Cancer 
Centre performed mutational analysis on genomic DNA extracted from tumours using the Illumina 
TruSeq™Amplicon Cancer Panel (TSACP) next-generation targeted exome screen using ~150 ng DNA 
per sample on the MiSeq platform [12]. This technology choice arose from the comprehensive hot-spot 
focus, FFPE compatibility, and low cost afforded by this product. Although Illumina’s TSCAP lacks 
sensitivity to copy number and structural changes, these activating events can be assayed cost-effectively 
using alternative testing modalities. Specific mutations (212 in total across 48 genes) were screened 
using DNA extracted from formalin fixed, paraffin-embedded (FFPE) unstained sections. Analyses of 
the technical considerations of identifying mutations screened have previously been published [10,12]. 
Assays were batched during these initial phase 1 collections where the emphasis was on feasibility.  
As such, the results of genomic cancer gene panel tests where not returned to clinicians in a timely 
fashion to guide patient treatment (except in rare instances where clinicians specifically requested  
fast-tracking of results) and any somatic variants identified were returned as a research finding. 
4.3. Data Collection 
Patients’ medical records were reviewed such that the Cancer 2015 registry contained a minimum set 
of clinical data including tumour histo-type, site, morphology, laterality, stage, treatment summary (surgery, 
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chemo-/radio-therapy) and intent (curative/palliative). In addition to patient demographics, the mode of 
presentation (symptomatic, incidental or screening), Charlson Index [19] of Co-morbidities from patient 
history, the Eastern Co-operative Oncology Group (ECOG) performance status [8] (clinically reported 
where possible) and a past history of cancer at both the personal and family (restricted to 2nd degree 
relatives) level, were all collected. Patients were asked to complete two patient reported outcome measures 
(PROMs) at the initial interview, the European Organization for Research and Treatment of Cancer 
(EORTC) QLQ-C30 [20] questionnaire and the EuroQol Group’s generic, preference based EQ-5D-3L [21] 
questionnaire. Collectively, these patient data, together with biospecimen sample identification, were 
housed in a secure, centralised database that was web-accessible across participating hospitals. 
4.4. Data Linkages 
Patients were also asked to consent to the extraction and linkage of individual data collated by the 
federal Department of Human Services (Australia) containing medical services and pharmaceutical 
resource use and expenditure (known respectively as the MBS and the PBS), as well as hospital 
administrative datasets provided by the Victorian Department of Health’s Data Linkages team. Such 
data of hospital admissions and emergency presentations of patients were provided to Cancer 2015 under 
several strict conditions (e.g., patient de-identification) regarding use and custodianship. 
4.5. Patient Follow up 
Patient follow up was performed at 6 and 12 months post-consent into the cohort, and continued every 
12 months thereafter. This timeline was accelerated for a subset of the cohort (~10%) consisting of 
advanced cancer patients with an extra follow up added at 3 months post-consent. Further follow up will 
be performed over a period of 5 years (funding permitted) for all participants to monitor for response to 
treatments, progression/relapse and survival outcomes. Follow up involves gathering up-to-date clinical 
data from hospital and pathological records, and further PROM responses (majority via mail out of the 
set of questionnaires) to track health outcomes over time. Where possible, blood collection was repeated 
for a subset of patients who re-visited the participating hospitals near the follow up time points (within 
1 month generally) for potential use in other studies which utilise plasma biomarkers for disease progression 
(e.g., circulating plasma tumour DNA dependent on protocol requirements). 
5. Conclusions 
It is increasingly clear that the implementation of a program of genomic medicine will require  
a population-level approach to screening and the identification of suitable cases for the future of clinical 
trials of targeted therapies [13,14]. Cancer 2015 has placed Victoria in an enviable position. It has  
a highly annotated clinical genomics registry whose data can be made available to ethically approved 
research upon application to the Steering Committee. 
  




Please see Table S1: Cancer 2015 Registry Completeness by Data Element (as at 1 July 2015), Table 
S2: Cancer 2015_Supplementary List of Data Elements, Files: Cancer2015_Illumina_TSCA_Cancer  
Gene Panel Targets.xls, Cancer2015_Actionable Mutations_Current Targeted Drugs.xls. 
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